The Impact of PCSK9 on Risk Factors for Ischemic Stroke and Potential Mechanisms  

作　　者：Zehua He Mingtian Lu Zhejing Ding Zhengwei Chen Tianyang Guan Zhongliang Li Cheng Zhou Haiquan Tao Guangsen Cheng Yu Liu Zehua He;Mingtian Lu;Zhejing Ding;Zhengwei Chen;Tianyang Guan;Zhongliang Li;Cheng Zhou;Haiquan Tao;Guangsen Cheng;Yu Liu(Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai Peoples Hospital), The First Affiliated Hospital of Faculty of Medicine Macao University of Science and Technology, Zhuhai, China)

机构地区：[1]Cerebrovascular Diseases Department, Zhuhai Clinical Medical College of Jinan University (Zhuhai Peoples Hospital), The First Affiliated Hospital of Faculty of Medicine Macao University of Science and Technology, Zhuhai, China

出　　处：《American Journal of Molecular Biology》2025年第1期110-122,共13页美国分子生物学期刊(英文)

摘　　要：Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell surface pathways, consequently elevating serum LDL-C levels. PCSK9 is implicated in various processes such as lipid metabolism, atherosclerosis, oxidative stress, inflammatory responses, thrombosis, and apoptosis. It is closely linked to ischemic stroke through its role in inducing and advancing atherosclerosis. PCSK9 inhibitors play a useful role in both acute and secondary prevention of ischemic stroke and can reduce the risk of ischemic stroke. This review examines the influence of PCSK9 on the risk factors associated with ischemic stroke and explores its potential mechanisms, and briefly describes the application of PCSK9 inhibitors in ischemic stroke.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell surface pathways, consequently elevating serum LDL-C levels. PCSK9 is implicated in various processes such as lipid metabolism, atherosclerosis, oxidative stress, inflammatory responses, thrombosis, and apoptosis. It is closely linked to ischemic stroke through its role in inducing and advancing atherosclerosis. PCSK9 inhibitors play a useful role in both acute and secondary prevention of ischemic stroke and can reduce the risk of ischemic stroke. This review examines the influence of PCSK9 on the risk factors associated with ischemic stroke and explores its potential mechanisms, and briefly describes the application of PCSK9 inhibitors in ischemic stroke.

关 键 词：Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Ischemic Stroke ATHEROSCLEROSIS INFLAMMATION 

分 类 号：R54[医药卫生—心血管疾病]